** Shares of Neurizon Therapeutics NUZ.AX rise as much as 3.2% to A$0.160, their biggest intraday pct gain since June 26
** The biotechnology co enters into a global licensing agreement with Elanco Animal Health ELAN.N
** Agreement is for exclusive rights to Elanco's data package and related intellectual property for Monepantel, the active pharmaceutical ingredient in co's NUZ-001, a formulation used in neurodegeneration applications
** YTD, shares of co down 5.9%
(Reporting by Nichiket Sunil in Bengaluru)
((Nichiket.Sunil@thomsonreuters.com))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。